Ketek Is Emerging As Lens For Wider Hill Scrutiny Of Clinical Trial Integrity
The House Energy and Commerce Committee's inquiries into Sanofi-Aventis' Ketek could be a jumping-off point for a wide-ranging congressional look into the integrity of clinical trials and oversight of companies involved in those trials
You may also be interested in...
Solithera's efficacy profile appears strong, but FDA has safety concerns, particularly its structural similarities to the controversial Ketek.
The antibiotic showed promising results in a late-stage study of the oral formulation, setting the company up as a potential target for acquirers and partnering opportunities – though for now it is signaling its intent to go it alone.
A limited population antibacterial drug pathway could reassure investors about the viability of antibiotics and help FDA avoid looking over its shoulder as it approves products based on limited data, though enactment is uncertain.